XML 82 R59.htm IDEA: XBRL DOCUMENT
v3.24.2

Segments of Business and Geographic Areas - Sales By Segment Of Business (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2024 | Jul. 02, 2023 | Jun. 30, 2024 | Jul. 02, 2023
Sales by segment of business |  |  |  |
Sales to customers | $ 22,447 | $ 21,519 | $ 43,830 | $ 42,413
Percent Change (as a percent) | 4.30% |  | 3.30% |
U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 12,569 | 11,657 | $ 24,189 | 22,439
Percent Change (as a percent) | 7.80% |  | 7.80% |
International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 9,878 | 9,862 | $ 19,641 | 19,974
Percent Change (as a percent) | 0.20% |  | (1.70%) |
MEDTECH |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 7,957 | 7,788 | $ 15,778 | 15,269
Percent Change (as a percent) | 2.20% |  | 3.30% |
MEDTECH | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 4,059 | 3,839 | $ 8,067 | 7,598
Percent Change (as a percent) | 5.70% |  | 6.20% |
MEDTECH | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3,898 | 3,949 | $ 7,711 | 7,671
Percent Change (as a percent) | (1.30%) |  | 0.50% |
MEDTECH | Cardiovascular(1) |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,873 | 1,620 | $ 3,679 | 3,123
Percent Change (as a percent) | 15.60% |  | 17.80% |
MEDTECH | Cardiovascular(1) | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,119 | 908 | $ 2,144 | 1,771
Percent Change (as a percent) | 23.30% |  | 21.10% |
MEDTECH | Cardiovascular(1) | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 753 | 712 | $ 1,534 | 1,352
Percent Change (as a percent) | 5.70% |  | 13.40% |
MEDTECH | ELECTROPHYSIOLOGY |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,323 | 1,196 | $ 2,667 | 2,288
Percent Change (as a percent) | 10.60% |  | 16.50% |
MEDTECH | ELECTROPHYSIOLOGY | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 705 | 609 | $ 1,397 | 1,180
Percent Change (as a percent) | 15.70% |  | 18.40% |
MEDTECH | ELECTROPHYSIOLOGY | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 618 | 587 | $ 1,270 | 1,109
Percent Change (as a percent) | 5.40% |  | 14.60% |
MEDTECH | ABIOMED |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 379 | 331 | $ 750 | 655
Percent Change (as a percent) | 14.50% |  | 14.50% |
MEDTECH | ABIOMED | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 309 | 272 | $ 612 | 536
Percent Change (as a percent) | 13.20% |  | 14.10% |
MEDTECH | ABIOMED | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 72 | 59 | $ 139 | 119
Percent Change (as a percent) | 20.70% |  | 16.50% |
MEDTECH | Shockwave |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 77 | 0 | $ 77 | 0
MEDTECH | Shockwave | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | 77 | 0 | 77 | 0
MEDTECH | Shockwave | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 0 | 0 | $ 0 | 0
Percent Change (as a percent) | 0.00% |  | 0.00% |
MEDTECH | OTHER CARDIOVASCULAR(1) |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 93 | 93 | $ 185 | 180
Percent Change (as a percent) | 0.30% |  | 2.90% |
MEDTECH | OTHER CARDIOVASCULAR(1) | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 29 | 27 | $ 59 | 55
Percent Change (as a percent) | 12.50% |  | 7.70% |
MEDTECH | OTHER CARDIOVASCULAR(1) | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 64 | 67 | $ 126 | 125
Percent Change (as a percent) | (4.50%) |  | 0.80% |
MEDTECH | Orthopaedics |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,312 | 2,265 | $ 4,652 | 4,510
Percent Change (as a percent) | 2.10% |  | 3.20% |
MEDTECH | Orthopaedics | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,422 | 1,388 | $ 2,870 | 2,751
Percent Change (as a percent) | 2.50% |  | 4.30% |
MEDTECH | Orthopaedics | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 890 | 878 | $ 1,782 | 1,759
Percent Change (as a percent) | 1.40% |  | 1.30% |
MEDTECH | Orthopaedics | HIPS |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 417 | 397 | $ 839 | 787
Percent Change (as a percent) | 4.90% |  | 6.50% |
MEDTECH | Orthopaedics | HIPS | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 265 | 250 | $ 535 | 491
Percent Change (as a percent) | 5.80% |  | 8.90% |
MEDTECH | Orthopaedics | HIPS | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 152 | 147 | $ 304 | 296
Percent Change (as a percent) | 3.40% |  | 2.60% |
MEDTECH | Orthopaedics | KNEES |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 394 | 363 | $ 795 | 731
Percent Change (as a percent) | 8.40% |  | 8.70% |
MEDTECH | Orthopaedics | KNEES | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 230 | 221 | $ 472 | 447
Percent Change (as a percent) | 4.20% |  | 5.50% |
MEDTECH | Orthopaedics | KNEES | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 163 | 142 | $ 323 | 284
Percent Change (as a percent) | 14.90% |  | 13.60% |
MEDTECH | Orthopaedics | TRAUMA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 759 | 739 | $ 1,524 | 1,496
Percent Change (as a percent) | 2.80% |  | 1.90% |
MEDTECH | Orthopaedics | TRAUMA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 498 | 483 | $ 1,002 | 974
Percent Change (as a percent) | 3.00% |  | 2.90% |
MEDTECH | Orthopaedics | TRAUMA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 260 | 255 | $ 521 | 522
Percent Change (as a percent) | 2.40% |  | 0.00% |
MEDTECH | Orthopaedics | SPINE, SPORTS & OTHER |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 743 | 766 | $ 1,495 | 1,495
Percent Change (as a percent) | (3.10%) |  | 0.00% |
MEDTECH | Orthopaedics | SPINE, SPORTS & OTHER | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 430 | 433 | $ 862 | 839
Percent Change (as a percent) | (0.80%) |  | 2.70% |
MEDTECH | Orthopaedics | SPINE, SPORTS & OTHER | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 314 | 334 | $ 634 | 657
Percent Change (as a percent) | (6.10%) |  | (3.50%) |
MEDTECH | Surgery |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,488 | 2,594 | $ 4,904 | 5,028
Percent Change (as a percent) | (4.10%) |  | (2.50%) |
MEDTECH | Surgery | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 995 | 1,015 | $ 1,982 | 1,990
Percent Change (as a percent) | (2.00%) |  | (0.40%) |
MEDTECH | Surgery | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,493 | 1,580 | $ 2,922 | 3,039
Percent Change (as a percent) | (5.50%) |  | (3.80%) |
MEDTECH | Surgery | ADVANCED |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,141 | 1,222 | $ 2,228 | 2,340
Percent Change (as a percent) | (6.70%) |  | (4.80%) |
MEDTECH | Surgery | ADVANCED | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 466 | 466 | $ 912 | 910
Percent Change (as a percent) | 0.10% |  | 0.20% |
MEDTECH | Surgery | ADVANCED | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 675 | 757 | $ 1,316 | 1,430
Percent Change (as a percent) | (10.80%) |  | (8.00%) |
MEDTECH | Surgery | GENERAL |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,346 | 1,372 | $ 2,676 | 2,688
Percent Change (as a percent) | (1.90%) |  | (0.50%) |
MEDTECH | Surgery | GENERAL | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 528 | 548 | $ 1,070 | 1,079
Percent Change (as a percent) | (3.70%) |  | (0.90%) |
MEDTECH | Surgery | GENERAL | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 818 | 823 | $ 1,606 | 1,608
Percent Change (as a percent) | (0.70%) |  | (0.20%) |
MEDTECH | Vision |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,285 | 1,308 | $ 2,543 | 2,608
Percent Change (as a percent) | (1.70%) |  | (2.50%) |
MEDTECH | Vision | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 523 | 529 | $ 1,070 | 1,087
Percent Change (as a percent) | (1.20%) |  | (1.50%) |
MEDTECH | Vision | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 763 | 778 | $ 1,473 | 1,521
Percent Change (as a percent) | (2.00%) |  | (3.20%) |
MEDTECH | Vision | CONTACT LENSES / OTHER |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 918 | 939 | $ 1,828 | 1,892
Percent Change (as a percent) | (2.20%) |  | (3.40%) |
MEDTECH | Vision | CONTACT LENSES / OTHER | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 409 | 409 | $ 847 | 853
Percent Change (as a percent) | 0.20% |  | (0.60%) |
MEDTECH | Vision | CONTACT LENSES / OTHER | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 509 | 530 | $ 981 | 1,039
Percent Change (as a percent) | (4.00%) |  | (5.60%) |
MEDTECH | Vision | SURGICAL |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 367 | 369 | $ 715 | 716
Percent Change (as a percent) | (0.50%) |  | (0.10%) |
MEDTECH | Vision | SURGICAL | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 113 | 120 | $ 223 | 234
Percent Change (as a percent) | (5.80%) |  | (4.80%) |
MEDTECH | Vision | SURGICAL | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 254 | 249 | $ 492 | 482
Percent Change (as a percent) | 2.10% |  | 2.10% |
Innovative Medicine |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 14,490 | 13,731 | $ 28,052 | 27,144
Percent Change (as a percent) | 5.50% |  | 3.30% |
Innovative Medicine | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 8,510 | 7,818 | $ 16,122 | 14,841
Percent Change (as a percent) | 8.90% |  | 8.60% |
Innovative Medicine | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 5,980 | 5,913 | $ 11,930 | 12,303
Percent Change (as a percent) | 1.10% |  | (3.00%) |
Innovative Medicine | Immunology |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 4,722 | 4,496 | $ 8,969 | 8,608
Percent Change (as a percent) | 5.00% |  | 4.20% |
Innovative Medicine | Immunology | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,978 | 2,865 | $ 5,431 | 5,313
Percent Change (as a percent) | 4.00% |  | 2.20% |
Innovative Medicine | Immunology | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,744 | 1,631 | $ 3,538 | 3,295
Percent Change (as a percent) | 6.90% |  | 7.40% |
Innovative Medicine | Immunology | REMICADE |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 393 | 462 | $ 827 | 949
Percent Change (as a percent) | (14.90%) |  | (12.90%) |
Innovative Medicine | Immunology | REMICADE | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 231 | 277 | $ 497 | 553
Percent Change (as a percent) | (16.70%) |  | (10.10%) |
Innovative Medicine | Immunology | REMICADE | U.S. Exports |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 35 | 33 | $ 62 | 74
Percent Change (as a percent) | 7.90% |  | (15.40%) |
Innovative Medicine | Immunology | REMICADE | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 127 | 152 | $ 268 | 322
Percent Change (as a percent) | (16.60%) |  | (16.90%) |
Innovative Medicine | Immunology | SIMPONI / SIMPONI ARIA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 537 | 529 | $ 1,091 | 1,066
Percent Change (as a percent) | 1.60% |  | 2.30% |
Innovative Medicine | Immunology | SIMPONI / SIMPONI ARIA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 267 | 285 | $ 521 | 556
Percent Change (as a percent) | (6.30%) |  | (6.20%) |
Innovative Medicine | Immunology | SIMPONI / SIMPONI ARIA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 270 | 244 | $ 569 | 510
Percent Change (as a percent) | 10.90% |  | 11.70% |
Innovative Medicine | Immunology | STELARA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,885 | 2,797 | $ 5,336 | 5,241
Percent Change (as a percent) | 3.10% |  | 1.80% |
Innovative Medicine | Immunology | STELARA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,855 | 1,817 | $ 3,251 | 3,268
Percent Change (as a percent) | 2.10% |  | (0.50%) |
Innovative Medicine | Immunology | STELARA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,030 | 981 | $ 2,085 | 1,974
Percent Change (as a percent) | 5.00% |  | 5.60% |
Innovative Medicine | Immunology | TREMFYA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 906 | 706 | $ 1,714 | 1,346
Percent Change (as a percent) | 28.30% |  | 27.30% |
Innovative Medicine | Immunology | TREMFYA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 589 | 450 | $ 1,098 | 856
Percent Change (as a percent) | 30.80% |  | 28.20% |
Innovative Medicine | Immunology | TREMFYA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 317 | 255 | $ 616 | 489
Percent Change (as a percent) | 23.90% |  | 25.80% |
Innovative Medicine | Immunology | OTHER IMMUNOLOGY |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2 | 4 | $ 2 | 7
Percent Change (as a percent) | (51.50%) |  | (75.40%) |
Innovative Medicine | Immunology | OTHER IMMUNOLOGY | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2 | 4 | $ 2 | 7
Percent Change (as a percent) | (51.50%) |  | (75.40%) |
Innovative Medicine | Immunology | OTHER IMMUNOLOGY | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 0 | 0 | $ 0 | 0
Percent Change (as a percent) | 0.00% |  | 0.00% |
Innovative Medicine | Infectious Diseases |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 965 | 1,121 | $ 1,786 | 2,707
Percent Change (as a percent) | (13.90%) |  | (34.00%) |
Innovative Medicine | Infectious Diseases | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 334 | 395 | $ 658 | 787
Percent Change (as a percent) | (15.40%) |  | (16.40%) |
Innovative Medicine | Infectious Diseases | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 631 | 727 | $ 1,128 | 1,920
Percent Change (as a percent) | (13.10%) |  | (41.30%) |
Innovative Medicine | Infectious Diseases | COVID-19 |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 172 | 285 | $ 197 | 1,032
Percent Change (as a percent) | (39.70%) |  | (80.90%) |
Innovative Medicine | Infectious Diseases | COVID-19 | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 0 | 0 | $ 0 | 0
Percent Change (as a percent) | 0.00% |  | 0.00% |
Innovative Medicine | Infectious Diseases | COVID-19 | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 172 | 285 | $ 197 | 1,032
Percent Change (as a percent) | (39.70%) |  | (80.90%) |
Innovative Medicine | Infectious Diseases | EDURANT / rilpivirine |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 297 | 266 | $ 620 | 546
Percent Change (as a percent) | 11.00% |  | 13.40% |
Innovative Medicine | Infectious Diseases | EDURANT / rilpivirine | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 8 | 8 | $ 16 | 17
Percent Change (as a percent) | (2.80%) |  | (7.00%) |
Innovative Medicine | Infectious Diseases | EDURANT / rilpivirine | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 288 | 258 | $ 603 | 529
Percent Change (as a percent) | 11.50% |  | 14.10% |
Innovative Medicine | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 438 | 491 | $ 856 | 968
Percent Change (as a percent) | (11.00%) |  | (11.60%) |
Innovative Medicine | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 321 | 382 | $ 635 | 760
Percent Change (as a percent) | (16.00%) |  | (16.50%) |
Innovative Medicine | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 117 | 109 | $ 221 | 208
Percent Change (as a percent) | 6.50% |  | 6.00% |
Innovative Medicine | Infectious Diseases | OTHER INFECTIOUS DISEASES( |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 61 | 79 | $ 114 | 161
Percent Change (as a percent) | (23.10%) |  | (29.30%) |
Innovative Medicine | Infectious Diseases | OTHER INFECTIOUS DISEASES( | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 5 | 5 | $ 7 | 10
Percent Change (as a percent) | 18.50% |  | (29.40%) |
Innovative Medicine | Infectious Diseases | OTHER INFECTIOUS DISEASES( | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 55 | 74 | $ 107 | 151
Percent Change (as a percent) | (25.60%) |  | (29.30%) |
Innovative Medicine | Neuroscience |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,782 | 1,793 | $ 3,585 | 3,597
Percent Change (as a percent) | (0.60%) |  | (0.30%) |
Innovative Medicine | Neuroscience | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,102 | 1,029 | $ 2,156 | 2,007
Percent Change (as a percent) | 7.10% |  | 7.40% |
Innovative Medicine | Neuroscience | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 679 | 764 | $ 1,428 | 1,590
Percent Change (as a percent) | (11.10%) |  | (10.20%) |
Innovative Medicine | Neuroscience | CONCERTA / methylphenidate |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 163 | 208 | $ 340 | 414
Percent Change (as a percent) | (21.50%) |  | (17.80%) |
Innovative Medicine | Neuroscience | CONCERTA / methylphenidate | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 34 | 64 | $ 75 | 134
Percent Change (as a percent) | (47.70%) |  | (44.30%) |
Innovative Medicine | Neuroscience | CONCERTA / methylphenidate | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 129 | 143 | $ 265 | 279
Percent Change (as a percent) | (9.80%) |  | (5.10%) |
Innovative Medicine | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,054 | 1,031 | $ 2,110 | 2,075
Percent Change (as a percent) | 2.20% |  | 1.70% |
Innovative Medicine | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 784 | 721 | $ 1,549 | 1,434
Percent Change (as a percent) | 8.80% |  | 8.00% |
Innovative Medicine | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 269 | 310 | $ 561 | 641
Percent Change (as a percent) | (13.10%) |  | (12.40%) |
Innovative Medicine | Neuroscience | SPRAVATO |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 271 | 169 | $ 496 | 300
Percent Change (as a percent) | 60.20% |  | 65.50% |
Innovative Medicine | Neuroscience | SPRAVATO | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 226 | 144 | $ 417 | 255
Percent Change (as a percent) | 57.90% |  | 63.90% |
Innovative Medicine | Neuroscience | SPRAVATO | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 44 | 25 | $ 78 | 45
Percent Change (as a percent) | 73.50% |  | 74.60% |
Innovative Medicine | Neuroscience | OTHER NEUROSCIENCE |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 294 | 386 | $ 639 | 809
Percent Change (as a percent) | (23.70%) |  | (21.00%) |
Innovative Medicine | Neuroscience | OTHER NEUROSCIENCE | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 57 | 100 | $ 115 | 184
Percent Change (as a percent) | (42.50%) |  | (37.30%) |
Innovative Medicine | Neuroscience | OTHER NEUROSCIENCE | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 237 | 286 | $ 524 | 625
Percent Change (as a percent) | (17.00%) |  | (16.20%) |
Innovative Medicine | Oncology |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 5,090 | 4,398 | $ 9,904 | 8,510
Percent Change (as a percent) | 15.70% |  | 16.40% |
Innovative Medicine | Oncology | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,636 | 2,069 | $ 5,019 | 3,958
Percent Change (as a percent) | 27.40% |  | 26.80% |
Innovative Medicine | Oncology | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,455 | 2,329 | $ 4,885 | 4,552
Percent Change (as a percent) | 5.40% |  | 7.30% |
Innovative Medicine | Oncology | CARVYKTI |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 186 | 117 | $ 343 | 189
Percent Change (as a percent) | 59.80% |  | 81.50% |
Innovative Medicine | Oncology | CARVYKTI | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 167 | 114 | $ 307 | 184
Percent Change (as a percent) | 46.50% |  | 66.80% |
Innovative Medicine | Oncology | CARVYKTI | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 20 | 3 | $ 36 | 5
Innovative Medicine | Oncology | DARZALEX |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,878 | 2,431 | $ 5,570 | 4,695
Percent Change (as a percent) | 18.40% |  | 18.60% |
Innovative Medicine | Oncology | DARZALEX | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,641 | 1,322 | $ 3,105 | 2,513
Percent Change (as a percent) | 24.20% |  | 23.60% |
Innovative Medicine | Oncology | DARZALEX | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,237 | 1,110 | $ 2,465 | 2,182
Percent Change (as a percent) | 11.50% |  | 12.90% |
Innovative Medicine | Oncology | ERLEADA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 736 | 567 | $ 1,425 | 1,109
Percent Change (as a percent) | 29.80% |  | 28.40% |
Innovative Medicine | Oncology | ERLEADA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 318 | 241 | $ 603 | 490
Percent Change (as a percent) | 32.20% |  | 23.00% |
Innovative Medicine | Oncology | ERLEADA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 418 | 326 | $ 822 | 619
Percent Change (as a percent) | 28.00% |  | 32.80% |
Innovative Medicine | Oncology | IMBRUVICA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 770 | 841 | $ 1,554 | 1,668
Percent Change (as a percent) | (8.50%) |  | (6.90%) |
Innovative Medicine | Oncology | IMBRUVICA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 246 | 262 | $ 511 | 532
Percent Change (as a percent) | (6.40%) |  | (3.90%) |
Innovative Medicine | Oncology | IMBRUVICA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 525 | 579 | $ 1,043 | 1,136
Percent Change (as a percent) | (9.40%) |  | (8.30%) |
Innovative Medicine | Oncology | ZYTIGA / abiraterone acetate |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 165 | 227 | $ 346 | 472
Percent Change (as a percent) | (27.70%) |  | (26.80%) |
Innovative Medicine | Oncology | ZYTIGA / abiraterone acetate | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 11 | 9 | $ 20 | 25
Percent Change (as a percent) | 21.60% |  | (19.70%) |
Innovative Medicine | Oncology | ZYTIGA / abiraterone acetate | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 154 | 218 | $ 326 | 447
Percent Change (as a percent) | (29.60%) |  | (27.20%) |
Innovative Medicine | Oncology | OTHER ONCOLOGY |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 221 | 120 | $ 399 | 219
Percent Change (as a percent) | 84.20% |  | 82.40% |
Innovative Medicine | Oncology | OTHER ONCOLOGY | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 148 | 40 | $ 267 | 75
Innovative Medicine | Oncology | OTHER ONCOLOGY | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 71 | 80 | $ 131 | 144
Percent Change (as a percent) | (10.40%) |  | (8.50%) |
Innovative Medicine | Oncology | Tecvayli |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 135 | 94 | $ 268 | 157
Percent Change (as a percent) | 42.90% |  | 70.20% |
Innovative Medicine | Oncology | Tecvayli | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 104 | 82 | $ 205 | 139
Percent Change (as a percent) | 27.50% |  | 47.70% |
Innovative Medicine | Oncology | Tecvayli | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 30 | 12 | $ 63 | 18
Innovative Medicine | Pulmonary Hypertension |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,039 | 972 | $ 2,088 | 1,844
Percent Change (as a percent) | 6.90% |  | 13.20% |
Innovative Medicine | Pulmonary Hypertension | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 743 | 684 | $ 1,509 | 1,284
Percent Change (as a percent) | 8.70% |  | 17.50% |
Innovative Medicine | Pulmonary Hypertension | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 296 | 289 | $ 579 | 561
Percent Change (as a percent) | 2.60% |  | 3.40% |
Innovative Medicine | Pulmonary Hypertension | OPSUMIT |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 544 | 507 | $ 1,068 | 947
Percent Change (as a percent) | 7.10% |  | 12.70% |
Innovative Medicine | Pulmonary Hypertension | OPSUMIT | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 373 | 328 | $ 729 | 601
Percent Change (as a percent) | 13.70% |  | 21.30% |
Innovative Medicine | Pulmonary Hypertension | OPSUMIT | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 170 | 179 | $ 339 | 346
Percent Change (as a percent) | (5.00%) |  | (2.20%) |
Innovative Medicine | Pulmonary Hypertension | UPTRAVI |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 426 | 399 | $ 894 | 761
Percent Change (as a percent) | 6.60% |  | 17.40% |
Innovative Medicine | Pulmonary Hypertension | UPTRAVI | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 349 | 338 | $ 741 | 642
Percent Change (as a percent) | 3.30% |  | 15.50% |
Innovative Medicine | Pulmonary Hypertension | UPTRAVI | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 76 | 61 | $ 152 | 119
Percent Change (as a percent) | 24.60% |  | 27.60% |
Innovative Medicine | Pulmonary Hypertension | Other |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 71 | 66 | $ 127 | 136
Percent Change (as a percent) | 7.20% |  | (6.50%) |
Innovative Medicine | Pulmonary Hypertension | Other | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 20 | 18 | $ 38 | 41
Percent Change (as a percent) | 18.80% |  | (6.10%) |
Innovative Medicine | Pulmonary Hypertension | Other | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 50 | 48 | $ 89 | 95
Percent Change (as a percent) | 3.10% |  | (6.70%) |
Innovative Medicine | Cardiovascular / Metabolism / Other |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 892 | 950 | $ 1,721 | 1,877
Percent Change (as a percent) | (6.20%) |  | (8.30%) |
Innovative Medicine | Cardiovascular / Metabolism / Other | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 717 | 776 | $ 1,348 | 1,491
Percent Change (as a percent) | (7.70%) |  | (9.60%) |
Innovative Medicine | Cardiovascular / Metabolism / Other | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 176 | 174 | $ 373 | 386
Percent Change (as a percent) | 0.60% |  | (3.60%) |
Innovative Medicine | Cardiovascular / Metabolism / Other | Other |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 305 | 313 | $ 616 | 662
Percent Change (as a percent) | (2.50%) |  | (7.00%) |
Innovative Medicine | Cardiovascular / Metabolism / Other | Other | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 129 | 138 | $ 243 | 275
Percent Change (as a percent) | (6.40%) |  | (11.80%) |
Innovative Medicine | Cardiovascular / Metabolism / Other | Other | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 176 | 174 | $ 373 | 386
Percent Change (as a percent) | 0.60% |  | (3.60%) |
Innovative Medicine | Cardiovascular / Metabolism / Other | XARELTO |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 587 | 637 | $ 1,105 | 1,215
Percent Change (as a percent) | (7.90%) |  | (9.10%) |
Innovative Medicine | Cardiovascular / Metabolism / Other | XARELTO | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 587 | 637 | $ 1,105 | 1,215
Percent Change (as a percent) | (7.90%) |  | (9.10%) |
Innovative Medicine | Cardiovascular / Metabolism / Other | XARELTO | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 0 | $ 0 | $ 0 | $ 0
Percent Change (as a percent) | 0.00% |  | 0.00% |

X
- Definition Percentage change in sales by segment of business. + References No definition available. + Details
Name: | jnj_PercentageChangeInSalesBySegmentOfBusiness
Namespace Prefix: | jnj_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationRevenueAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_CardiovascularMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_ElectrophysiologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_AbiomedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_ShockwaveMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OtherCardiovascularMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_HIPSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_KNEESMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TRAUMAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SPINEOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_SurgeryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ADVANCEDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_GENERALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_VisionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SURGICALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_InnovativeMedicineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_ImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_StelaraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TremfyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_COVID19Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SPRAVATOMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CARVYKTIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_DARZALEXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ERLEADAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_IMBRUVICAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ZYTIGAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherOncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TecvayliMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OPSUMITMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_UPTRAVIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_XareltoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |